Cytek Biosciences to Report Second Quarter 2024 Financial Results on August 6, 2024
31 July 2024 - 6:05AM
Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis
solutions company, today announced it will report financial results
for the second quarter 2024 after market close on Tuesday, August
6, 2024. The company’s management will webcast a corresponding
conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m.
Eastern Time to discuss its results, business developments and
outlook.
Live audio of the webcast will be available on the “Investors”
section of the company website at investors.cytekbio.com.
About Cytek Biosciences, Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis
solutions company advancing the next generation of cell analysis
tools by delivering high-resolution, high-content and
high-sensitivity cell analysis utilizing its patented Full Spectrum
Profiling™ (FSP™) technology. Cytek’s novel approach harnesses the
power of information within the entire spectrum of a fluorescent
signal to achieve a higher level of multiplexing with precision and
sensitivity. Cytek’s platform includes its core instruments, the
Cytek Aurora™ and Northern Lights™ systems; its cell sorter, the
Cytek Aurora CS; the flow cytometer and imaging products under the
Amnis® and Guava® brands; the Cytek Orion™ reagent
cocktail preparation system, and reagents, software and services to
provide a comprehensive and integrated suite of solutions for its
customers. Cytek is headquartered in Fremont, California with
offices and distribution channels across the globe. More
information about the company and its products is available
at www.cytekbio.com.
Cytek’s products are for research use only and not for use in
diagnostic procedures (other than Cytek’s Northern Lights-CLC
system and certain reagents, which are available for clinical use
in China and the European Union).
Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern
Lights, Cytek Orion, Amnis and Guava are trademarks of Cytek
Biosciences, Inc.
In addition to filings with the Securities and Exchange
Commission (SEC), press releases, public conference calls and
webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page
and X (formerly Twitter) account as channels of distribution of
information about its company, products, planned financial and
other announcements, attendance at upcoming investor and industry
conferences and other matters. Such information may be deemed
material information and Cytek may use these channels to comply
with its disclosure obligations under Regulation FD. Therefore,
investors should monitor Cytek’s website, LinkedIn page, and X
account in addition to following its SEC filings, news releases,
public conference calls and webcasts.
Media Contact:Stephanie OlsenLages &
Associates(949) 453-8080stephanie@lages.com
Investor Contact:Paul GoodsonHead of Investor
RelationsCytek Biosciencespgoodson@cytekbio.com
Cytek Biosciences (NASDAQ:CTKB)
Historical Stock Chart
From Sep 2024 to Oct 2024
Cytek Biosciences (NASDAQ:CTKB)
Historical Stock Chart
From Oct 2023 to Oct 2024